Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical announced the progress of a Phase II clinical trial for XH-S004 tablets, developed by its subsidiary Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., for treating non-cystic fibrosis bronchiectasis in China. The drug, a small molecule oral DPP-1 inhibitor, is also being tested for chronic obstructive pulmonary disease, with clinical trials approved in China. The company has invested approximately RMB 61 million in the R&D of XH-S004 as of April 2025, highlighting its commitment to advancing treatment options in respiratory diseases.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, focusing on the pharmaceutical industry. The company is involved in the development and production of various pharmaceutical products, with a particular emphasis on innovative drug research and development.
Average Trading Volume: 4,672,541
Technical Sentiment Signal: Hold
Current Market Cap: HK$62.27B
See more data about 2196 stock on TipRanks’ Stock Analysis page.